Lp-PLA 2 as a risk factor of early neurological deterioration in acute ischemic stroke with TOAST type of large arterial atherosclerosis.

Introduction: Lipoprotein-associated phospholipase A ₂ (Lp-PLA ₂ ) is a well-known risk factor of atherosclerotic vascular diseases. Nevertheless, its role in the acute phase of ischemic stroke is still unclear. The aim of this study is to identify the relationship between Lp-PLA ₂ levels and early neurological deterioration (END) in acute ischemic stroke patients with Trial of Org 10 172 in Acute Stroke Treatment (TOAST) subtype of large arterial atherosclerosis (LAA). Methods: We enrolled Chinese patients with first ever acute ischemic stroke admitted to Neurology Department of Shenzhen Second People's Hospital within 48 h from onset of symptoms during January - November 2015. Demographic and laboratory information were collected while END was defined as an increase in the National Institute of Health Stroke Scale score by ≥ 1 point in motor power, or ≥ 2 points in the total score within 10 days after admission. Results: Overall 181 patients were involved; END was diagnosed in 30 patients within 10 days after admission. The odds ratio for END increased with increasing levels of Lp-PLA ₂ (intermediate level, OR = 1.96, 95%CI 1.02-4.27, p  = 0.041; high level, OR = 2.99, 95%CI 1.26-5.73, p  = 0.023). Conclution: Intermediate and high level of Lp-PLA ₂ was identified as independent predictor of END in multivariate analysis. Lp-PLA ₂ could be valued as a risk factor of END in patients with acute ischemic stroke with TOAST subtype of LAA.